Mycobacterial MenG: Partial Purification, Characterization, and Inhibition

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Menaquinone (MK) is crucial for the electron transport chain (ETC) in Mycobacterium tuberculosis and other Gram-positive pathogens.
• Three genes in M. tuberculosis were initially annotated as methyltransferases involved in lipoquinone synthesis.

Purpose of the Study:

• To identify and characterize the methyltransferase responsible for menaquinone synthesis in Mycobacterium tuberculosis.
• To investigate the enzymatic activity and substrate specificity of the Rv0558 protein.
• To evaluate the inhibitory potential of known compounds against the identified enzyme.

Main Methods:

• Heterologous expression of Rv0558 in Escherichia coli to assess its menaquinone methyltransferase activity.
• Enzymatic assays using partially purified recombinant Rv0558 and membrane preparations from M. smegmatis.
• Determination of kinetic parameters (Km) and evaluation of cofactor/substrate stimulation.
• Inhibition assays using Ro 48-8071 and DG70 (GSK1733953A).

Main Results:

• Rv0558 functions as a demethylmenaquinol methyltransferase (MenG), catalyzing MK formation from demethylmenaquinone (DMK).
• Enzyme activity was enhanced in the presence of cofactors or intact membrane structures and stimulated by various substrates.
• Demethylmenaquinol and S-adenosylmethionine (SAM) were identified as substrates with specific Km values.
• Ro 48-8071 and DG70 inhibited MenG activity with IC50 values of 5.1 ± 0.5 μM and 2.6 ± 0.6 μM, respectively.

Conclusions:

• Rv0558 is confirmed as the menaquinone-specific methyltransferase (MenG) in M. tuberculosis, with demethylmenaquinol as its substrate.
• The study provides insights into the menaquinone biosynthesis pathway and identifies potential drug targets for tuberculosis.
• The identified inhibitors demonstrate the therapeutic potential of targeting MenG for anti-mycobacterial drug development.